Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04219969 · ClinicalTrials.gov registry record · NA
FDG PET-MRI for the Diagnosis of Spinal Cord Lesions
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT04219969: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT04219969 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04219969, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.
Interventions
- PROCEDURE Positron Emission Tomography
- DEVICE Magnetic Resonance Imaging
- DRUG Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2024-05-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04219969
The ClinicalTrials.gov registry entry for NCT04219969 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography is the first listed.
NCT04219969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04219969 about?
NCT04219969 is a clinical study titled "FDG PET-MRI for the Diagnosis of Spinal Cord Lesions". To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.
What is the current status of trial NCT04219969?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2018-09-21. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT04219969?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Magnetic Resonance Imaging (DEVICE), Fludeoxyglucose F-18 (DRUG).
Who is sponsoring clinical trial NCT04219969?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.